Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A randomized double – blind Placebo- controlled international multicenter study. Study assessing the morbi - mortality benefits of the If inhibitor Ivad
DATE – 2011 -2013
Name of the specialist – Hayrapetyan G.G.
Role – Principal Investigator
(SIGNIFY study, study protocol CL3-16257 - 083) – International multicenter double –blind placebo-controlled research SIGNIFY (protocol of research CL3-16257 - 083), Scientific article in European Haert Journal 2014, lectures on the Congress of European Assosiation of Cardiology in Barcelona, 2014.
Jointly participating Organization – Servier Laboratories (France) (Gagik Velijanyan, www.servier.com/)
Result – effectiveness of ivabradine during the stable ischemic heart disease with safe fraction of the left ventricle emission is not proved
Publications – scientific article in European Heart Journal, 2014